September - 2013
| Previous Next | Showing Journal 11 of 12 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular CoagulationJean-Louis Vincent, Mayakonda K Ramesh, David Ernest, et al Crit Care Med, 2013, 41(9):2069–2079. doi:10.1097/CCM.0b013e31828e9b03. This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
September |
Previous Comments
No Comments yet.
Comment
This phase 2b RCT compared ART-123 (soluble recombinant human thrombomodulin that acts by reducing thrombin-mediated clotting and enhancing protein C activation at the site of clotting, and has anti-inflammatory properties including interfering with the activation of complement and...